BioCentury | Oct 25, 2019
Tools & Techniques

NASH: how non-invasive biomarkers promise to displace biopsies

...do early stage development programs where we rely on biopsy. That’s not practical." Williamson Bradford, Indalo...
...tools, according to ClinicalTrials.gov. At least two more are planning to do so. Anti-fibrotic play Indalo Therapeutics Inc....
...markers Indalo plans to use to enroll patients in its upcoming Phase I trial. BMS, Indalo...
BioCentury | Feb 16, 2019
Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

...million ($14.8 million) from Decheng Capital (see “Decheng Backs Nanjing Bioheng in Series A” ). Indalo Therapeutics Inc....
...3; STING (TMEM173) - Transmembrane protein 173 BC Staff Arvelle Therapeutics GmbH Culture Biosciences Inc. Grey Wolf Therapeutics IFM Therapeutics LLC Indalo Therapeutics Inc. Neurogene...
BioCentury | Feb 14, 2019
Emerging Company Profile

Indalo: Integral to fibrosis

...to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling. Indalo...
...as the promotion of fibroblast migration and survival by stiff extracellular matrix (ECM). “We at Indalo...
...antagonists licensed from St. Louis University; Jacks said Indalo is still working on those compounds. Indalo...
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

...NASDAQ:SNY). Koenig succeeds Tao Fu, who was chief commercial and business officer. Fibrotic disease company Indalo Therapeutics Inc....
...President and CFO of Symbiomix Therapeutics LLC, which Lupin Ltd. (NSE:LUPIN; BSE:500257) acquired in 2017. Indalo...
BioCentury | Oct 24, 2016
Company News

Antegrin, Cascadia deal

...Antegrin and Cascadia merged to form Indalo Therapeutics Inc. (St. Louis, Mo.). The newco is developing treatments for...
...Louis University (St. Louis, Mo.). The newco plans to start clinical trials in early 2019. Indalo...
Items per page:
1 - 5 of 5
BioCentury | Oct 25, 2019
Tools & Techniques

NASH: how non-invasive biomarkers promise to displace biopsies

...do early stage development programs where we rely on biopsy. That’s not practical." Williamson Bradford, Indalo...
...tools, according to ClinicalTrials.gov. At least two more are planning to do so. Anti-fibrotic play Indalo Therapeutics Inc....
...markers Indalo plans to use to enroll patients in its upcoming Phase I trial. BMS, Indalo...
BioCentury | Feb 16, 2019
Company News

Emerging company roundup: Passage, IFM, Grey Wolf, Culture

...million ($14.8 million) from Decheng Capital (see “Decheng Backs Nanjing Bioheng in Series A” ). Indalo Therapeutics Inc....
...3; STING (TMEM173) - Transmembrane protein 173 BC Staff Arvelle Therapeutics GmbH Culture Biosciences Inc. Grey Wolf Therapeutics IFM Therapeutics LLC Indalo Therapeutics Inc. Neurogene...
BioCentury | Feb 14, 2019
Emerging Company Profile

Indalo: Integral to fibrosis

...to disrupt disease-associated processes, not just those driven by a single integrin or TGFβ signaling. Indalo...
...as the promotion of fibroblast migration and survival by stiff extracellular matrix (ECM). “We at Indalo...
...antagonists licensed from St. Louis University; Jacks said Indalo is still working on those compounds. Indalo...
BioCentury | Jan 28, 2019
Company News

Management tracks: Ironwood reveals board for new companies

...NASDAQ:SNY). Koenig succeeds Tao Fu, who was chief commercial and business officer. Fibrotic disease company Indalo Therapeutics Inc....
...President and CFO of Symbiomix Therapeutics LLC, which Lupin Ltd. (NSE:LUPIN; BSE:500257) acquired in 2017. Indalo...
BioCentury | Oct 24, 2016
Company News

Antegrin, Cascadia deal

...Antegrin and Cascadia merged to form Indalo Therapeutics Inc. (St. Louis, Mo.). The newco is developing treatments for...
...Louis University (St. Louis, Mo.). The newco plans to start clinical trials in early 2019. Indalo...
Items per page:
1 - 5 of 5